Gilead Sciences to Acquire Repare Therapeutics' RP-3467 for Up to $30M
ByAinvest
Saturday, Dec 27, 2025 5:36 am ET1min read
GILD--
RPTX--
Gilead Sciences has acquired Repare Therapeutics' RP-3467, a polymerase theta ATPase inhibitor, for up to $30m. The deal includes a $25m upfront payment and up to $5m upon completion of technology transfer activities. The acquisition has increased Repare's cash reserves, raising the estimate for shareholder payments to $2.20 per common share upon closing the arrangement transaction. RP-3467 is a potent small molecule inhibitor of Polθ, linked to breast cancer gene mutations and other genomic alterations.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet